NanoString Technologies Appoints Senior Financial Executive Greg Norden to Board of Directors
<0> For NanoString TechnologiesNicole Litchfield, 415-793-6468 </0>
NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the appointment of Greg Norden, former Chief Financial Officer of Wyeth, to its Board of Directors. Mr. Norden will serve as the Chairman of NanoString’s Audit Committee.
Mr. Norden is a senior executive with more than 25 years of leadership in financial management and strategy, including a 21-year career at Wyeth, where he was most recently Senior Vice President and Chief Financial Officer. Wyeth was acquired by Pfizer in October 2009 in a transaction valued at $68 billion. Prior to his corporate CFO role, Mr. Norden was Executive Vice President and Chief Financial Officer, Wyeth Pharmaceuticals and held a number of other positions of increasing responsibility from initially joining Wyeth/American Home Products in 1989. Earlier in his career, Mr. Norden worked at Arthur Andersen & Co.
“With a rapidly growing life sciences business and a capability for developing high-value molecular diagnostics, NanoString Technologies is poised to transform both the study and treatment of disease,” said Mr. Norden. “I am excited to join NanoString’s Board of Directors, and to help the company scale these businesses.”
Mr. Norden received his B.S. from the State University of New York – Plattsburgh and received his M.S. from Long Island University – C. W. Post. He also serves on the Board of Directors of Human Genome Sciences (NASDAQ: HGSI), a public biopharmaceutical company, and WelchAllyn, a leading global provider of medical diagnostic equipment.
“Greg brings more than two decades of healthcare industry experience and an impeccable track record of leading financial and administrative operations,” said William D. Young, Executive Chairman of the Board for NanoString Technologies. “We look forward to benefiting from his experience as CFO of a global Fortune 120 corporation as we prepare for the next stage of NanoString’s growth.”
More information is available at .
NanoString Technologies is a privately held provider of life science tools for translational research and developer of molecular diagnostics. The company’s nCounter Analysis System is the first and only technology platform to deliver highly multiplexed, direct profiling of individual molecules in a single reaction without amplification. The nCounter Analysis System offers a cost-effective way to easily profile hundreds of gene transcripts, copy number variations, or miRNAs simultaneously with high sensitivity and precision. The company’s technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. NanoString is also developing the technology for use in molecular diagnostics.